Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications

Jing He, Lei Huo, Junsheng Ma, Jun Zhao, Roland L. Bassett, Xiaoping Sun, Naoto T. Ueno, Bora Lim, Yun Gong

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives Inflammatory breast carcinoma (IBC) is rare but is the most lethal type of breast cancer. Programmed death ligand 1 (PD-L1) expression in IBCs has been understudied. Methods In this study, tissue microarrays of 68 IBCs were immunostained with a PD-L1 antibody using an antibody clone (28-8) and detection system approved by the US Food and Drug Administration for selecting patients with non-small cell lung cancer and melanoma for anti-PD-L1 therapy. Results Positive PD-L1 expression was found in 25 (36.8%) of 68 samples but was not significantly associated with the clinicopathologic variables examined. Univariate analysis of overall survival (OS) revealed that worse OS was significantly associated with positive PD-L1, negative estrogen receptor, and triple-negative status. The 5-year OS rate was 36.4% for patients with PD-L1-positive IBC and 47.3% for those with PD-L1-negative IBC. In multivariate analyses, PD-L1 status remained a statistically independent predictor of OS. Conclusions These findings indicate that PD-L1 inhibitors could potentially improve the clinical outcome of patients with PD-L1-positive IBC.

Original languageEnglish (US)
Pages (from-to)253-261
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume149
Issue number3
DOIs
StatePublished - Feb 17 2018
Externally publishedYes

Fingerprint

Inflammatory Breast Neoplasms
Ligands
Survival
Antibodies
United States Food and Drug Administration
Survival Analysis
Non-Small Cell Lung Carcinoma
Estrogen Receptors
Melanoma
Multivariate Analysis
Survival Rate
Clone Cells

Keywords

  • Breast
  • Immunohistochemistry
  • Inflammatory breast cancer
  • PD-L1
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. / He, Jing; Huo, Lei; Ma, Junsheng; Zhao, Jun; Bassett, Roland L.; Sun, Xiaoping; Ueno, Naoto T.; Lim, Bora; Gong, Yun.

In: American Journal of Clinical Pathology, Vol. 149, No. 3, 17.02.2018, p. 253-261.

Research output: Contribution to journalArticle

He, Jing ; Huo, Lei ; Ma, Junsheng ; Zhao, Jun ; Bassett, Roland L. ; Sun, Xiaoping ; Ueno, Naoto T. ; Lim, Bora ; Gong, Yun. / Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. In: American Journal of Clinical Pathology. 2018 ; Vol. 149, No. 3. pp. 253-261.
@article{df5bc556d35c4fb0ac46ba457e9e560a,
title = "Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications",
abstract = "Objectives Inflammatory breast carcinoma (IBC) is rare but is the most lethal type of breast cancer. Programmed death ligand 1 (PD-L1) expression in IBCs has been understudied. Methods In this study, tissue microarrays of 68 IBCs were immunostained with a PD-L1 antibody using an antibody clone (28-8) and detection system approved by the US Food and Drug Administration for selecting patients with non-small cell lung cancer and melanoma for anti-PD-L1 therapy. Results Positive PD-L1 expression was found in 25 (36.8{\%}) of 68 samples but was not significantly associated with the clinicopathologic variables examined. Univariate analysis of overall survival (OS) revealed that worse OS was significantly associated with positive PD-L1, negative estrogen receptor, and triple-negative status. The 5-year OS rate was 36.4{\%} for patients with PD-L1-positive IBC and 47.3{\%} for those with PD-L1-negative IBC. In multivariate analyses, PD-L1 status remained a statistically independent predictor of OS. Conclusions These findings indicate that PD-L1 inhibitors could potentially improve the clinical outcome of patients with PD-L1-positive IBC.",
keywords = "Breast, Immunohistochemistry, Inflammatory breast cancer, PD-L1, Prognosis, Survival",
author = "Jing He and Lei Huo and Junsheng Ma and Jun Zhao and Bassett, {Roland L.} and Xiaoping Sun and Ueno, {Naoto T.} and Bora Lim and Yun Gong",
year = "2018",
month = "2",
day = "17",
doi = "10.1093/ajcp/aqx162",
language = "English (US)",
volume = "149",
pages = "253--261",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications

AU - He, Jing

AU - Huo, Lei

AU - Ma, Junsheng

AU - Zhao, Jun

AU - Bassett, Roland L.

AU - Sun, Xiaoping

AU - Ueno, Naoto T.

AU - Lim, Bora

AU - Gong, Yun

PY - 2018/2/17

Y1 - 2018/2/17

N2 - Objectives Inflammatory breast carcinoma (IBC) is rare but is the most lethal type of breast cancer. Programmed death ligand 1 (PD-L1) expression in IBCs has been understudied. Methods In this study, tissue microarrays of 68 IBCs were immunostained with a PD-L1 antibody using an antibody clone (28-8) and detection system approved by the US Food and Drug Administration for selecting patients with non-small cell lung cancer and melanoma for anti-PD-L1 therapy. Results Positive PD-L1 expression was found in 25 (36.8%) of 68 samples but was not significantly associated with the clinicopathologic variables examined. Univariate analysis of overall survival (OS) revealed that worse OS was significantly associated with positive PD-L1, negative estrogen receptor, and triple-negative status. The 5-year OS rate was 36.4% for patients with PD-L1-positive IBC and 47.3% for those with PD-L1-negative IBC. In multivariate analyses, PD-L1 status remained a statistically independent predictor of OS. Conclusions These findings indicate that PD-L1 inhibitors could potentially improve the clinical outcome of patients with PD-L1-positive IBC.

AB - Objectives Inflammatory breast carcinoma (IBC) is rare but is the most lethal type of breast cancer. Programmed death ligand 1 (PD-L1) expression in IBCs has been understudied. Methods In this study, tissue microarrays of 68 IBCs were immunostained with a PD-L1 antibody using an antibody clone (28-8) and detection system approved by the US Food and Drug Administration for selecting patients with non-small cell lung cancer and melanoma for anti-PD-L1 therapy. Results Positive PD-L1 expression was found in 25 (36.8%) of 68 samples but was not significantly associated with the clinicopathologic variables examined. Univariate analysis of overall survival (OS) revealed that worse OS was significantly associated with positive PD-L1, negative estrogen receptor, and triple-negative status. The 5-year OS rate was 36.4% for patients with PD-L1-positive IBC and 47.3% for those with PD-L1-negative IBC. In multivariate analyses, PD-L1 status remained a statistically independent predictor of OS. Conclusions These findings indicate that PD-L1 inhibitors could potentially improve the clinical outcome of patients with PD-L1-positive IBC.

KW - Breast

KW - Immunohistochemistry

KW - Inflammatory breast cancer

KW - PD-L1

KW - Prognosis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85042541614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042541614&partnerID=8YFLogxK

U2 - 10.1093/ajcp/aqx162

DO - 10.1093/ajcp/aqx162

M3 - Article

VL - 149

SP - 253

EP - 261

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -